Big Pharma, Bigger Milestones
Does Big Pharma tend to make higher milestone payments in development deals than other types of licensees?
You may also be interested in...
Productivity in biotech is a better problem to have than its opposite-but paying the higher-than-expected development costs makes it still a problem. Thanks to a variety of new project financing sources, and a particularly clever approach to amending its alliance with GlaxoSmithKline, Exelixis is fact trying to turn research productivity into a source of non-dilutive capital.
Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.